Dermatitis

Regal Lager Launches Terra Premium Plant-Based Diapers and Wipes in the United States and Canada

Retrieved on: 
Thursday, June 8, 2023
Honey, Starch, Paraben, Vitamin E, Function, Parent, Regal Lager, Inc., Training pants, Vitamin, LaTeX, Dry, Aloe vera, Chlorine, Water, Irritation, The Non-GMO Project, Terra, PLA, Dermatitis, FSC, Skin, Safety, Tissue paper, Cosmetics, Amazon

ATLANTA, June 8, 2023 /PRNewswire/ -- Baby and children's products distributor, Regal Lager, announced today that it is now distributing New Zealand based Terra's premium plant-based diapers and wipes in the U.S. and Canada.

Key Points: 
  • Terra Diapers and Training Pants are made from 85% plant-based materials and boast 360 degree absorbency, instant dryness, and 12+ hours of protection against wetness.
  • Terra's eco-friendly wipes are made from 100% biodegradable FSC-certified bamboo fiber (not bamboo viscose) and 99.5+% pure New Zealand water.
  • Terra's Bamboo Wipes are available in three options:
    Using crystal clear New Zealand water, Terra Wipes provide a naturally simple, yet nourishing cleanse for your baby.
  • "Regal Lager is thrilled to offer Terra's unparalleled diapers and wipes to parents in North America and cannot wait to see the positive effect the products have on their daily lives," said Bengt Lager, President of Regal Lager.

IFF Receives NIS Golden Açaí Award for HOWARU® Probiotic Strain in the Applied Ingredient Category

Retrieved on: 
Monday, June 5, 2023
PMID, Food, Exhibition, Prevalence, Dermatitis, Pediatric Allergy and Immunology, All rights reserved, Quality of life, Atopic dermatitis, Lacticaseibacillus rhamnosus, Science, Creativity, NYSE, SM, Risk, Allergy, NIS, Pregnancy, Probiotic, SAO, Dietary supplement, Bifidobacterium, Lactobacillus, Lacticaseibacillus, Health

SAO PAULO, June 5, 2023 /PRNewswire/ -- IFF today announced its HOWARU® probiotic strain Lacticaseibacillus rhamnosus HN001® has won the NIS Golden Açaí Awards' Applied Ingredients category. The award, presented at a ceremony in São Paulo, is given in recognition of IFF's HOWARU® HN001® strain contribution to reducing the risk of eczema. The inaugural award ceremony was held alongside the Nutri Ingredients Summit (NIS), an exhibition and conference that focuses on functional ingredients from May 30-31.

Key Points: 
  • SAO PAULO, June 5, 2023 /PRNewswire/ -- IFF today announced its HOWARU® probiotic strain Lacticaseibacillus rhamnosus HN001® has won the NIS Golden Açaí Awards' Applied Ingredients category.
  • The inaugural award ceremony was held alongside the Nutri Ingredients Summit (NIS), an exhibition and conference that focuses on functional ingredients from May 30-31.
  • The theme of this year's award is "The ingredient as a fundamental factor for innovation in the industry".
  • IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted.

Expanded Care Options at B.C. Pharmacies: Pharmacists Empowered to Treat 21 Minor Ailments with New Prescribing Powers

Retrieved on: 
Thursday, June 1, 2023
Antler, Allergy, ER, Headache, Pharmacy, Urinary tract infection, Birth, Hemorrhoid, Prescription, Dermatitis, Shingles, ID, Government, Pharmacist, Patient, Glycine mollis, Health, Conjunctivitis, Pharmasave, Hormonal contraception, Candidiasis, Health insurance, Birth control

pharmacists now have prescribing abilities for common ailments and hormonal contraception, which previously required visiting a doctor or nurse practitioner.

Key Points: 
  • pharmacists now have prescribing abilities for common ailments and hormonal contraception, which previously required visiting a doctor or nurse practitioner.
  • “Engaging pharmacists for the treatment of minor ailments is not only about convenience, but also a matter of improving patient care and expanding primary healthcare capacity.
  • would have to see a doctor or nurse practitioner to obtain prescription treatment for minor ailments.
  • “Assessing symptoms, evaluating medication needs, and offering patients recommendations to treat minor ailments are part of the care provided every day by pharmacists in our communities.

Dermatologist Dr. Ellen Turner Attends BTL Aesthetics & Wellness Summit and More

Retrieved on: 
Tuesday, May 30, 2023
Omni, Rosacea, Dermatitis, The Resort, Elastin, Dermatology, Skin cancer, Acne, Newport Beach, California, Psoriasis, Irving, Laser, Brown Palace Hotel (Denver), Collagen, Diagnosis, Patient, AI, Bird, Skin, BTL, Medical device

EMFACE™ addresses both muscle tone and the overlying skin issues through the combined use of radiofrequency and high frequency electrostimulation energies.

Key Points: 
  • EMFACE™ addresses both muscle tone and the overlying skin issues through the combined use of radiofrequency and high frequency electrostimulation energies.
  • It can also be used with other lasers, such as the newest BTL device, Exion, which combines monopolar radiofrequency (RF) and AI.
  • Beyond the BTL summit, Dr. Turner’s team also attended this year’s SkinMedica® VIP Summit held at The Brown Palace Hotel and Spa in Denver, Colo., May 18 to 20.
  • Dr. Turner provides diagnosis and care for various types of skin diseases and disorders at her Dallas and Irving offices.

Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

Retrieved on: 
Tuesday, May 23, 2023
Science, Veterinary, Biotechnology, Research, Pharmaceutical, Pets, Health, Consumer, Human, Partnership, London Stock Exchange, Marketing, Veterinarian, Dermatitis, Veterinary medicine, Atopic dermatitis, Multimedia, Dechra Pharmaceuticals, Dermatology, London, Dog, Growth, Therapy, ILC, Vaccine

Scottish biotech ILC Therapeutics has signed a R&D partnership with Dechra Pharmaceuticals PLC which will see international veterinary group Dechra and ILC Therapeutics develop ILC’s Caniferon product to treat atopic dermatitis in dogs.

Key Points: 
  • Scottish biotech ILC Therapeutics has signed a R&D partnership with Dechra Pharmaceuticals PLC which will see international veterinary group Dechra and ILC Therapeutics develop ILC’s Caniferon product to treat atopic dermatitis in dogs.
  • Atopic dermatitis is the most common form of eczema affecting humans and canines, with the global canine market for atopic dermatitis exceeding $1bn.
  • View the full release here: https://www.businesswire.com/news/home/20230523005576/en/
    Scottish biotech ILC Therapeutics has signed a R&D partnership with Dechra Pharmaceuticals PLC (Photo: Business Wire)
    Dechra is a global specialist in veterinary pharmaceuticals and related products.
  • Dr Alan Walker, CEO of ILC Therapeutics, said: “While ILC’s main focus to date has been around human health, the partnership with Dechra is a validation of our technology and the potential to develop products in the animal health market.

Green Goo Expands Partnership with FabFitFun via Summer Add On 2023 Event and Summer & Fall 2023 Refills Programs

Retrieved on: 
Wednesday, May 24, 2023
Bruise, Calendula, Congestion, Allergy, Β-Carotene, Ginkgo biloba, Arthritis, Dermatitis, Eucalyptus, Plant, Sale, Psoriasis, Lycopene, Ginger, Chamomile, DIY, Beauty, Oil, Arnica, Irritation, Tin, Perfume

LYONS, Colo., May 24, 2023 /PRNewswire/ -- Green Goo, the plant-based Sierra Sage Herbs body care brand, is pleased to announce that it is expanding its range of offerings with leading lifestyle membership program FabFitFun. With over a million subscribers, FabFitFun delivers seasonal subscription boxes featuring a curation of full-sized products across beauty, fashion, fitness, home, tech, DIY and more.

Key Points: 
  • With over a million subscribers, FabFitFun delivers seasonal subscription boxes featuring a curation of full-sized products across beauty, fashion, fitness, home, tech, DIY and more.
  • "Our continued relationship with FabFitFun has become a vital part of our annual consumer outreach strategy," said Green Goo Co-Founder Jodi Scott.
  • Further, Green Goo's revolutionary Plants for Your Pits Clarity + Focus deodorant will feature in FabFitFun's Summer and Fall 2023 Refills program, which allows members to opt-in to receive curated products with each seasonal box.
  • For more information on Green Goo and its all-natural, plant-based products, please visit www.GreenGoo.com and follow @greengoohelps .

Nutricosmetics Formulation Expert & Microbiome Author Joins Codex Labs Medical Advisory Board

Retrieved on: 
Monday, May 22, 2023
Dermatitis, Ageing, Acne, Inflammation, Psoriasis, Silicon, Dermatology, Immune system, Bacteria, Health, Skin, Codex

San Jose, CA, May 22, 2023 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley bio-skintech company, and Paula Simpson, nutricosmetics formulator, author and microbiome expert, recently announced the addition of Paula to the Codex Labs medical advisory board.

Key Points: 
  • San Jose, CA, May 22, 2023 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley bio-skintech company, and Paula Simpson, nutricosmetics formulator, author and microbiome expert, recently announced the addition of Paula to the Codex Labs medical advisory board.
  • Our goal is to expand our ingestibles from acne to other skin conditions, and clinically prove and publish their efficacy through research studies with our medical advisory board dermatologists,”  said Dr. Barbara Paldus, Founder and CEO of Codex Labs.
  • "I'm thrilled to be a part of Codex Labs’ incredible team of medical, microbiome science & ethnobotany experts.
  • With my integrated background, I hope to support Codex Labs in bringing forth unique and personalized formulations for healthy, balanced skin inside and out," stated Paula Simpson, Author & Founder of Nutribloom Consulting.

Sami Nallamshetty, MD, FACAAI Uses Immunotherapy as a Powerful Tool to Treat Asthma and Allergies

Retrieved on: 
Friday, May 19, 2023
Allergen, Allergy, Hornet, Asthma, AAFA, Bee, Education, Sinusitis, Wheeze, Dermatitis, Season, Immunotherapy, Pollen, Research, National Institute of Food and Agriculture, William Frankland (allergist), Harvard Medical School, Patient, Dog, Asthma and Allergy Foundation of America, Dust, Immune system, Wiregrass, Cat, Agriculture, Hospital, Health, Wasp, Disease, Nursing, Pharmaceutical industry, Vaccine

It might even prevent the development of asthma in some children with seasonal allergies.

Key Points: 
  • It might even prevent the development of asthma in some children with seasonal allergies.
  • Both traditional and cluster immunotherapy (an accelerated version of allergy shots) are then administered in the office.
  • Clinical studies have shown they decrease symptoms, medication use and can even prevent new allergies and asthma in children.
  • "I am down from 5 allergy medications to 1 medication to treat my allergies!” proclaimed one of Dr. Nallamshetty’s patients.

NEW RESEARCH REVEALS MOST CRITICAL FACTORS FOR ECZEMA PATIENTS IN CONSIDERING A CLINICAL TRIAL

Retrieved on: 
Thursday, May 11, 2023
Research strategies of election campaign communication research, Parent, Dermatitis, Clinical trial, Research, Associate, NEA, Community, Patient, Risk, Child, Caregiver, Safety, Birth control, Pharmaceutical industry

NOVATO, Calif., May 11, 2023 /PRNewswire/ -- The National Eczema Association (NEA) today announced the first publication from its real-world research on clinical trial awareness and preferences among eczema patients and caregivers.

Key Points: 
  • NOVATO, Calif., May 11, 2023 /PRNewswire/ -- The National Eczema Association (NEA) today announced the first publication from its real-world research on clinical trial awareness and preferences among eczema patients and caregivers.
  • However, before eczema treatments can become available to patients, they must go through a lengthy and rigorous clinical trial process to make sure they are safe and effective.
  • NEA wanted to understand what goes into the clinical trial decision-making process, and conducted a survey to see what factors are most important to the eczema community when considering whether or not to participate in a clinical trial.
  • The survey asked participants to rate the importance of various factors when considering clinical trial participation.

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 9, 2023
Janus, PDE4, SG, Marketing, Hair, Food, New Drug Application, JAK1, Food and Drug Administration, NDA, Atopic dermatitis, Inflammation, Scalp, Psoriasis, Alopecia areata, Dermatitis, Shanda, Investment, Webcast, Pivotal, Growth, Ageing, R, Vitiligo, Research, FDA, Health Canada, Video game, Pharmaceutical industry, Nursing, Vaccine, Fine chemical, Cosmetics, Risk management, Cryptocurrency

The Company anticipates submitting a supplemental New Drug Application (sNDA) to the FDA for ages 6 and above late in the third quarter or early in the fourth quarter of 2023.

Key Points: 
  • The Company anticipates submitting a supplemental New Drug Application (sNDA) to the FDA for ages 6 and above late in the third quarter or early in the fourth quarter of 2023.
  • In September 2022, Arcutis announced positive topline results from the ARRECTOR Pivotal Phase 3 trial for the treatment of scalp and body psoriasis.
  • Research and development (R&D) expenses for the quarter ended March 31, 2023 were $35.3 million compared to $40.6 million for the corresponding period in 2022.
  • Arcutis management will host a conference call and webcast today at 4:30pm ET to discuss the financial results for the quarter and provide a business update.